Topic: Neurodegenerative Disorders

« Back

Print this page

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

	Sunday, 28. June 2009	next day »

No.	P-05 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Neurodegenerative Disorders
Session title:	Neurodegenerative Disorders I
	Alexandre Dailliet, Belgium	Chair

001	Regular moderate physical exercise improves mood and quality of life in older patients with atrial fibrillation
	Christine Norra, Germany	Presenter
002	EEG complexity in Alzheimer’s disease: Multiscale entropy analysis
	Tomoyuki Mizuno, Japan	Presenter
003	Rivastigmine and behavioral disorder of the patients in the centers for old persons
	Aleksandar Miljatovic, Serbia and Montenegro	Presenter
004	Cerebrolysin in the treatment of dementia mixed type and Alzheimer’s disease
	Andreea Silvana Szalontay, Romania	Presenter
005	Safety, efficacy, and biomarker findings of PBT2 in targeting ?-amyloid as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial
	Olivia Dean, Australia	Presenter
006	The implication of oxidative stress in a rat model of Parkinson's disease
	Ciobica Alin, Romania	Presenter
008	Crime or illness? The mystery of Frontotemporal Dementias
	Franziskos Xepapadakos, Switzerland	Presenter
009	Donepezil reverses beta-amyloid-induced deficits in long term potentiation in rat hippocampal slices
	Elena Solntseva, Russia	Presenter
010	Benefit of analyzing biological markers in cerebrospinal fluid in diagnosing Alzheimer’s during a consultation with an expert from a Centre Mémoire de Ressources et de Recherche
	Danièle Bentué-Ferrer, France	Presenter
011	Effects of apolipoprotein E genotype on behavioral and psychological symptoms in Alzheimer’s disease
	Shin-Gyeom Kim, Korea, Republic of	Presenter
013	Examining gene-gene interactions between tau haplotypes and ApoE4 in Alzheimer’s disease
	Péter Álmos, Hungary	Presenter
014	Creutzfeldt-Jakob dementia and psychiatric symptoms
	José de Santiago Sastre, Spain	Presenter
015	Symptomatic treatment of delirium
	José de Santiago Sastre, Spain	Presenter
016	Classifying what? How dementia classifications shape the concept of “normal” aging
	Lara Katharina Kutschenko, Germany	Presenter
017	Inflammatory biomarkers in Alheimer’s Disease: Clinical correlates
	Anton Alvarez, Spain	Presenter
018	Dementia caused by Sanfilippo B syndrome
	Willem Verhoeven, Netherlands	Presenter
019	Pharmacotherapy in intellectual disabilities
	Willem Verhoeven, Netherlands	Presenter
020	White matter lesions in Korsakoff syndrome
	Willem Verhoeven, Netherlands	Presenter

No.	S-19 - Symposium
Time:	14.00-15.30
Room:	Room 351
Topic:	Neurodegenerative Disorders
Track:	2 Clinical
Session title:	Early diagnosis of Alzheimers disease
	Bruno Dubois, France	Chair
	Harald Hampel, Germany	Co-Chair

001	Clinical and prognostic heterogeneity of mild cognitive impairment
	Orestes V. Forlenza, Brazil	Speaker
002	The role CSF biomarkers in the identification of AD at pre-dementia stages
	Harald Hampel, Germany	Speaker
003	Imaging of amyloid-beta in Alzheimers disease
	Swen Hesse, Germany	Speaker
004	For a new concept and new criteria for the diagnosis of Alzheimer’s disease
	Bruno Dubois, France	Speaker

No.	TG-02 - WFSBP Treatment Guidelines
Time:	16.00-17.30
Room:	Room 242A
Topic:	Neurodegenerative Disorders
Session title:	Psychogeriatrics
	Cornelius Katona, United Kingdom	Chair

	Constantine Lyketsos, USA	Presenter
	Claudia Cooper, United Kingdom	Presenter
	Carlos Augusto de Mendonca Lima, Portugal	Presenter
	Gill Livingston, United Kingdom	Presenter

« previous day	Monday, 29. June 2009	next day »

No.	FC-09 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Neurodegenerative Disorders
Session title:	Neurodegenerative Disorders
	Cornelius Katona, United Kingdom	Chair
	Anne Eckert, Switzerland	Co-Chair

001	Effects of Chinese herb Danshen-Dahuang on learning, memory ability and hippocampal gene expression of APP, PS1, BACE in rats with Alzheimer disease
	Bai Han, China, People's Republic of	Speaker
002	Relations of regional cerebral perfusion, atrophy and functional genetic variants in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
	Christian Luckhaus, Germany	Speaker
003	Centers of interest in Alzheimer patients, focus on apathy
	Daniel Dachesky, Argentina	Speaker
004	Brain iron accumulation as a risk factor for neurodegenerative disorders
	George Bartzokis, USA	Speaker
005	The clinical and neurobiological overlap between the major psychoses and frontotemporal dementia: More than a frontotemporal coincidence?
	Dennis Velakoulis, Australia	Speaker
006	Subthalamic neuronal activity in patients with obsessive-compulsive disorders or parkinson's disease
	Marie-Laure Welter, France	Speaker

No.	S-32 - Symposium
Time:	11.00-12.30
Room:	Salle Maillot
Topic:	Neurodegenerative Disorders
Track:	3 Interface
Session title:	Depression and dementia: Stress hormones and neuroprotection
	Edith Holsboer-Trachsler, Switzerland	Chair
	Luc Staner, France	Co-Chair

001	Role of neurosteroids and oxidative stress in neurodegeneration
	Anne Eckert, Switzerland	Speaker
002	Neuropeptide regulation and sleep in aging and depression
	Axel Steiger, Germany	Speaker
003	Can hormones provide natural neuroprotectivity: Melatonin and estrogen in neurodegeneration?
	Egemen Savaskan, Switzerland	Speaker
004	Antidepressants, age related sleep alterations and depression
	Luc Staner, France	Speaker

No.	S-42 - Symposium
Time:	16.00-17.30
Room:	Room 251
Topic:	Neurodegenerative Disorders
Track:	1 Basic
Session title:	Neurobiology of Alzheimer's disease: Beyond the amyloid hypothesis
	Orestes V. Forlenza, Brazil	Chair
	Russell H. Swerdlow, USA	Co-Chair

001	Alzheimer's disease, vascular dementia, or both?
	Donald R. Royall, USA	Speaker
002	The GSK-3 hypothesis of Alzheimer's disease
	Simon Lovestone, United Kingdom	Speaker
003	Phospholipids, phospholipase A2 and membrane abnormalities in Alzheimer's disease
	Wagner F. Gattaz, Brazil	Speaker
004	Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
	Russell H. Swerdlow, USA	Speaker

« previous day	Tuesday, 30. June 2009	next day »

No.	S-52 - Symposium
Time:	11.00-12.30
Room:	Room 241
Topic:	Neurodegenerative Disorders
Track:	3 Interface
Session title:	Clinical and biological aspect of apathy in neuropsychiatry
	Philippe Robert, France	Chair
	Albert Leentjens, Netherlands	Co-Chair

001	The concept of apathy in Alzheimer's disease
	Albert Leentjens, Netherlands	Speaker
002	Apathy in other neurodegenerative diseases
	Kathy Dujardin, France	Speaker
003	Ambulatory actigraphy for the evaluation of apathy in Alzheimer's disease
	Renaud David, France	Speaker
004	Discussion
	Philippe Robert, France	Speaker

No.	P-24 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Neurodegenerative Disorders
Session title:	Neurodegenerative Disorders II
	Serge Gauthier, Canada	Chair

001	Peculiarities and treatment of delirium in geriatrics patients with traumatic injuries
	Liubov Romasenko, Russia	Presenter
002	Effects of glycine on learning, memory ability and hippocampal gene expression of APP, PS1, BACE in rats with Alzheimer disease
	Bai Han, China, People's Republic of	Presenter
003	Study on Chinese herb Danshen-Dahuang on learning, memory ability and hippocampal Tau and Aß in rats with Alzheimer disease
	Bai Han, China, People's Republic of	Presenter
004	The study on the level of intestinal endotoxemia in Alzheimer’s disease rats
	Bai Han, China, People's Republic of	Presenter
005	Amisulpride in the treatment of very late onset schizophrenia
	Constantin Psarros, Greece	Presenter
007	Behavior and attention disorders at the children with intellectual disabilities
	Dragana Macesic-Petrovic, Serbia and Montenegro	Presenter
008	Age-dependent induction of neurofibrillary tangles in transgenic mice overexpressing a non-mutant human tau isoform
	Etsuko Oshima, Japan	Presenter
009	Exploratory efficacy in cross-maze test depends on neurochemical profile of brain
	Georgy Kovalev, Russia	Presenter
010	Enhancing resilience to stress and quality of life in depressed family dementia caregivers: A randomized placebo-controlled trial of escitalopram
	Helen Lavretsky, USA	Presenter
012	Comparison of frontotemporal dementia and healthy volunteers using quantative EEG
	Keiichiro Nishida, Japan	Presenter
013	The role of oxidative stress in Mild Cognitive Impairment and Alzheimer disease
	Manuela Padurariu, Romania	Presenter
014	Creatine deficiency syndrome: Study of a cohort of 530 patients in the CHU of Rouen
	Marc Chévrier, France	Presenter
015	Persistence of abnormal cortisol levels in elderly persons after recovery from major depression
	Marie Laure Ancelin, France	Presenter
016	Tactile perception in children with intellectual disabilities
	Mirjana Japundza-Milisavljevic, Serbia and Montenegro	Presenter
017	Depression in Parkinson’s disease: Serotonin mechanisms, response to SSRI antidepressants
	Natalya Demchuk, Russia	Presenter
018	Copper binding effect on amyloid peptide aggregation in Alzheimer's disease
	Nuria Durany, Spain	Presenter
019	Memory performance in patients with obstructive sleep apnea before and after positive airway pressure
	Perbal Séverine, France	Presenter
020	Psychosis in Parkinson’s disease patients: The relevance of dopaminergic drugs and of their mode of application
	Ronald Saurugg, Austria	Presenter
021	Switching strategy involving Galantamine in the treatment of patients with mild to moderate Alzheimers disease
	Tae-Young Hwang, Korea, Republic of	Presenter

No.	S-54 - Symposium
Time:	16.00-17.30
Room:	Blue Amphitheatre
Topic:	Neurodegenerative Disorders
Track:	1 Basic
Session title:	Aß Immunotherapy of Alzheimer's disease
	Siegfried Kasper, Austria	Chair
	Serge Gauthier, Canada	Co-Chair

001	Selection of efficacy outcomes in disease-modifying trials that are meaningful to clinicians, patients and payers
	Serge Gauthier, Canada	Speaker
002	Biomarkers in Alzheimer's disease: Use for clinical trials
	Anton Alvarez, Spain	Speaker
003	AD vaccines: The new generation - successes and challenges on its way into clinical practice
	Achim Schneeberger, Austria	Speaker
004	AFFITOPES of Aß as active vaccines in the treatment of AD: results of a phase I study with AFFITOPE AD02
	Alexandra Kutzelnigg, Austria	Speaker

« previous day	Wednesday, 1. July 2009	next day »

No.	S-62 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Neurodegenerative Disorders
Track:	2 Clinical
Session title:	Lithium, neuroprotection and dementia
	Wagner F. Gattaz, Brazil	Chair
	Husseini Manji, USA	Co-Chair

001	Neuroprotective effects of lithium: in vitro and in vivo models
	Husseini Manji, USA	Speaker
002	Does lithium protect against dementia? Evidence from clinical and genetic studies.
	Wagner F. Gattaz, Brazil	Speaker
003	Epidemiological evidence on the effects of lithium on the prevalence of dementia
	Lars Vedel Kessing, Denmark	Speaker
004	Lithium for the treatment of mild cognitive impairment: Preliminary results of a double-blind, placebo controlled trial
	Orestes V. Forlenza, Brazil	Speaker

« previous day	Thursday, 2. July 2009

No.	TG-10 - WFSBP Treatment Guidelines
Time:	14.00-15.30
Room:	Room 242A
Topic:	Neurodegenerative Disorders
Session title:	Dementia
	Masatoshi Takeda, Japan	Chair

	Ralf Ihl, Germany	Presenter
	Serge Gauthier, Canada	Presenter

« Back

---